Gefitinib represents a targeted small-molecule inhibitor designed to block epidermal growth factor receptor signaling pathways. Medical oncologists frequently select this agent for patients with specific mutation profiles in non-small cell lung cancer based on molecular testing outcomes. Treatment effectiveness depends significantly on tumor genetics and disease characteristics, making proper diagnostic evaluation essential prior to therapy initiation. Patients considering this medication should engage in detailed discussions with their treating physicians about expected outcomes, potential adverse reactions, and monitoring requirements throughout the treatment course.